Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1864536 | 0.89 | TRPV1 (0.49) | TRPV1MRGPRX4MAOAKCNH2MAPK3 | |
| SCHEMBL1863118 | 0.89 | TRPV1 (0.44) | TRPV1MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL1863373 | 0.87 | TRPV1 (0.46) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1858042 | 0.85 | TRPV1 (0.41) | TRPV1MRGPRX4 | |
| SCHEMBL1859475 | 0.85 | TRPV1 (0.42) | TRPV1MRGPRX4 | |
| SCHEMBL1860932 | 0.81 | TRPV1 (0.45) | TRPV1MAOAKCNH2MAPK3 | |
| SCHEMBL1862806 | 0.79 | TRPV1 (0.35) | TRPV1MRGPRX4MAOAKCNH2 | |
| SCHEMBL1866320 | 0.79 | TRPV1 (0.59) | TRPV1MRGPRX4MAOAKCNH2 | |
| SCHEMBL1867816 | 0.76 | TRPV1 (0.49) | TRPV1MRGPRX4MAOAKCNH2MAPK3 | |
| SCHEMBL1862452 | 0.75 | TRPV1 (0.46) | TRPV1MRGPRX4MAOAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1811845-A4 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORP (US) | 2009-07-15 | — | — | EP | disclosed |
| EP-1811845-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2006042289-A2 | SUBSTITUTED BIARYL QUINOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885MAPK1 3423/4885PIK3CA 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.